Arakis Limited
Focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy.
Launch date
Market cap
-
Enterprise valuation
CAD192m (Public information from Jul 2005)
London England (HQ & founding location)
Date | Investors | Amount | Round |
---|---|---|---|
£4.0m | Early VC | ||
£16.0m | Series B | ||
£29.0m | Series C | ||
£107m Valuation: £107m | Acquisition | ||
Total Funding | CAD88.2m |
Related Content
Recent News about Arakis Limited
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.